GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business

GE HealthCare (GEHC) will acquire privately held Sofie Biosciences for $945M in cash, gaining US rights to FAPI-74, a PET imaging agent in late-stage testing. The deal strengthens GEHC's radiopharma business, adding products for its imaging systems and increasing exposure to the growing radiopharmaceuticals market. The transaction is expected to close in the first half of 2027.

Original reporting
Published Oct 5, 2026, 1:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business — source image
Decision brief

The 30-second read

$GEHCBullishHigh
01

Why it matters

The acquisition positions GEHC to capture a larger share of the growing PET imaging drug market, potentially boosting revenue streams.

02

Market read

The deal is a material M&A event for a major U.S. healthcare company, likely influencing its stock and the radiopharma sector.

03

What to watch

Regulatory approval for the experimental PET agent and potential competition from other radiopharma players.

Relevance 9/10Novelty 9/10Timing: immediate

Background

GE HealthCare is expanding its diagnostic imaging business through strategic acquisitions, following its $2.3B purchase of Intelerad earlier this year.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE HealthCare announced a $945 million cash acquisition of Sofie Biosciences, expanding its radiopharma portfolio.

Expected impact

likely upward pressure as the market prices in the strategic expansion.

Evidence & confidence

Large‑scale M&A in a growth segment typically lifts the acquirer’s stock on the news.

Market effects

Strengthens GEHC's position in the radiopharmaceuticals market, potentially prompting competitors to consider similar moves.

U.S. healthcare and imaging sectors may see increased investor interest.

Adds to broader consolidation trends in medical imaging and diagnostics worldwide.

Counterpoint

If integration challenges arise, the acquisition could strain GEHC's balance sheet and dilute focus.

Key entities

  • GE HealthCare

    U.S.-listed medical device and diagnostics firm.

  • Sofie Biosciences

    Privately held radiopharma developer owned by Trilantic.

Related articles

$GEHCMed

GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software

GE HealthCare received FDA clearance for Critical Care Suite 3.0, an AI software for feeding tube detection in X-ray imaging. The software supports both adult and pediatric patients, enhancing the company's AI-enabled imaging portfolio. GEHC shares rose 2% post-announcement, with a market cap of $37.51B. The software demonstrated high accuracy in testing, potentially increasing demand for GEHC's mobile imaging systems.

$GEHCMed

GE HealthCare Lands FDA Clearance for On-Device Feeding Tube AI

GE HealthCare received FDA clearance for Critical Care Suite 3.0, an AI software for mobile X-ray devices that detects feeding tubes in adults and children. The algorithm, running on-device, achieved 99.2% sensitivity and 91.6% localization accuracy. The company aims to enhance ICU and emergency department workflows, with plans for further AI releases in 2027.

$GEHCMedAI 9/10

GE HealthCare Technologies Inc.: GE HealthCare's Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

GE HealthCare (GEHC) announced positive Phase 2 results for its MRI contrast agent mangaciclanol, meeting the primary endpoint and showing similar diagnostic preference to gadobutrol. The trial will advance to Phase 3, with mangaciclanol receiving FDA Fast Track designation. GEHC plans to present preliminary results at RSNA 2026.

$GEHCMed

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

GE HealthCare (GEHC) announced positive Phase 2 results for its MRI contrast agent mangaciclanol, advancing it to Phase 3 trials. The agent showed similar diagnostic performance to gadolinium-based agents and was well-tolerated. GEHC aims to address concerns with current contrast agents, such as tissue retention and supply chain issues. The FDA has granted mangaciclanol Fast Track designation.